Mucins and their role in shaping the functions of mucus barriers

CE Wagner, KM Wheeler… - Annual review of cell and …, 2018 - annualreviews.org
We review what is currently understood about how the structure of the primary solid
component of mucus, the glycoprotein mucin, gives rise to the mechanical and biochemical …

Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers

R Pangeni, T Meng, S Poudel, D Sharma… - International journal of …, 2023 - Elsevier
Airway mucus is a complex viscoelastic gel that provides a defensive physical barrier and
shields the airway epithelium by trapping inhaled foreign pathogens and facilitating their …

Promotion of skin regeneration through co-axial electrospun fibers loaded with basic fibroblast growth factor

J Chen, G Zhang, Y Zhao, M Zhou, A Zhong… - … composites and hybrid …, 2022 - Springer
Cutaneous wound healing is complex, requiring a coordinated response by growth factors,
drugs, and resident cells of the skin. To simulate native extracellular matrix, electrospun …

[HTML][HTML] N-acetyl cysteine-loaded graphene oxide-collagen hybrid membrane for scarless wound healing

J Li, C Zhou, C Luo, B Qian, S Liu, Y Zeng, J Hou… - Theranostics, 2019 - ncbi.nlm.nih.gov
Wound dressings composed of natural polymers, such as type I collagen, possess good
biocompatibility, water holding capacity, air permeability, and degradability, and can be …

Models using native tracheobronchial mucus in the context of pulmonary drug delivery research: composition, structure and barrier properties

BC Huck, X Murgia, S Frisch, M Hittinger… - Advanced Drug Delivery …, 2022 - Elsevier
Mucus covers all wet epithelia and acts as a protective barrier. In the airways of the lungs,
the viscoelastic mucus meshwork entraps and clears inhaled materials and efficiently …

Therapeutic antibodies–natural and pathological barriers and strategies to overcome them

Y Al Ojaimi, T Blin, J Lamamy, M Gracia, A Pitiot… - Pharmacology & …, 2022 - Elsevier
Antibody-based therapeutics have become a major class of therapeutics with over 120
recombinant antibodies approved or under review in the EU or US. This therapeutic class …

Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano–bio interactions

M Zhang, H Lu, L Xie, X Liu, D Cun, M Yang - Advanced Drug Delivery …, 2023 - Elsevier
In recent years, RNA-based therapies have gained much attention as biomedicines due to
their remarkable therapeutic effects with high specificity and potency. Lung diseases offer a …

Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin

L Müller, X Murgia, L Siebenbürger… - Journal of …, 2018 - academic.oup.com
Objectives In the context of cystic fibrosis, Pseudomonas aeruginosa biofilms often develop
in the vicinity of airway mucus, which acts as a protective physical barrier to inhaled matter …

[HTML][HTML] Impact of mucus modulation by N-acetylcysteine on nanoparticle toxicity

E Meziu, K Shehu, M Koch, M Schneider… - International Journal of …, 2023 - Elsevier
Human respiratory mucus is a biological hydrogel that forms a protective barrier for the
underlying epithelium. Modulation of the mucus layer has been employed as a strategy to …

[HTML][HTML] An optimized protocol for assessment of sputum macrorheology in health and muco-obstructive lung disease

M Völler, A Addante, H Rulff, B von Lospichl… - Frontiers in …, 2022 - frontiersin.org
Background: Airway mucus provides important protective functions in health and abnormal
viscoelasticity is a hallmark of muco-obstructive lung diseases such as cystic fibrosis (CF) …